Biogen and Elan Lose Market Value as Tysabri® Withdrawn
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 58 (Table of Contents)
Published: 5 Apr-2005
DOI: 10.3833/pdr.v2005.i58.692 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Biogen's and Elan's share values decline due to the withdrawal of the companies’ multiple sclerosis drug, Tysabri® from the market...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS